Your browser doesn't support javascript.
loading
Recalcitrant oral squamous cell papilloma lesions in two HIV-infected patients successfully treated with topical imiquimod.
Esquivel-Pedraza, Lilly; Fernández-Cuevas, Laura; Saeb-Lima, Marcela; Guerrero-Ramos, Brenda Alicia; Hernández-Salazar, Amparo; Méndez-Flores, Silvia.
Afiliação
  • Esquivel-Pedraza L; Dermatology Department, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", México City, Mexico;
  • Fernández-Cuevas L; Oral Pathology Department, Centro Dermatológico "Dr. Ladislao de la Pascua", México City, Mexico;
  • Saeb-Lima M; Pathology Department, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", México City, Mexico.
  • Guerrero-Ramos BA; Dermatology Department, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", México City, Mexico;
  • Hernández-Salazar A; Dermatology Department, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", México City, Mexico;
  • Méndez-Flores S; Dermatology Department, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", México City, Mexico;
J Dermatol Case Rep ; 9(1): 19-22, 2015 Mar 31.
Article em En | MEDLINE | ID: mdl-25932059
BACKGROUND: Squamous cell papilloma is a benign mucosal disease associated with human papillomavirus. Its presence in human immunodeficiency virus (HIV)-infected patients has rarely been reported. Therapeutic modalities for oral squamous cell papilloma have limited success and recurrences are frequent in HIV-infected subjects. Imiquimod, is a topical immunomodulator successfully used in some human papillomavirus-related oral lesions. However, its use for oral squamous cell papillomas in HIV-infected individuals has never been described. OBSERVATIONS: We report two male adult patients with HIV-infection, B2 and C3 stage respectively, undergoing antiretroviral therapy, with multiple recalcitrant oral squamous cell papillomas, predominantly affecting the masticatory mucosa. These lesions were successfully treated with daily topical imiquimod 5% cream for a few weeks, with only mild and well-tolerated side effects. No recurrences were observed after a follow-up period of over 20 months. CONCLUSIONS: Our cases highlight the value of imiquimod for the non-invasive treatment of multiple persistent oral squamous cell papillomas in two HIV-infected patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article